Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espa ñol de Trasplante Hematopoyético (GETH)

Plerixafor (Mozobil, Sanofi) is approved for using in patients with lymphoma and multiple myeloma when steady-state mobilization strategies fail. Although off-label use of plerixafor in healthy related donors (HRD) is known, limited data is available and no recommendations exist to guide its use in this setting. With the aim of collecting data from HRDs who received plerixafor in our country, we designed an observational case series study within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH).

Source: Transfusion and Apheresis Science - January 11, 2021 Category: Hematology Authors: Joan Cid, Silvia Monsalvo, Carlos Castillo, Cristina Pascual, Gemma Moreno-Jim énez, Miriam López-Parra, Concepción Andón, Luisa Guerra, Albert Esquirol, Isabel Sánchez-Ortega, Sandra Ortega, Saioa Zalba, Carmen Martínez, Montserrat Rovira, Pedro Ma Source Type: research